StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Full-Year Adjusted R&D Expense Guidance by Quarter

Full-Year Adjusted R&D Expense Guidance — Lower end ($M) ($M)

Pfizer Full-Year Adjusted R&D Expense Guidance: $10,500M in Q2 2026, up 1.0% from a year earlier.

Latest, Q2 2026
10,500
Period ended Jun 28, 2026
Change on a year earlier
+1.0%
10,400 in Q2 2025
History
29 quarters
Since Q1 2018
Sources
29
Documents cited below

Where the Q2 2026 figure comes from

“|| Adjusted (3) R&D Expenses ($ in billions) | $10.5 to $11.5 | $10.5 to $11.5”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Full-Year Financial Guidance Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFull-Year Adjusted R&D Expense Guidance — Lower end ($M) ($M)Year on yearSource
Q2 2026Jun 28, 202610,500+1.0%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 202610,500-1.9%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 202510,000-9.1%Form 8-K (Earnings / Guidance Release) (pfe-12162025xexh99.htm, filed 2025-12-16) ↗
Q3 2025Sep 28, 202510,000-9.1%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 202510,400-5.5%Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2025Mar 30, 202510,700-2.7%Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2024Dec 31, 202411,000-7.6%Form 8-K (Earnings / Guidance Release) (pfe-12172024xexh99.htm, filed 2024-12-17) ↗
Q3 2024Sep 29, 202411,000-7.6%Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2024Jun 30, 202411,000-11.3%Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 202411,000-11.3%Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q4 2023Dec 31, 202311,900–Form 8-K (Earnings / Guidance Release) (exh99pr121323.htm, filed 2023-12-13) ↗
Q3 2023Oct 1, 202311,900+3.5%Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2023Jul 2, 202312,400+7.8%Form 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2023Apr 2, 202312,400+12.7%Form 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗
Q3 2022Oct 2, 202211,500+10.6%Form 8-K (Earnings / Guidance Release) (pfe-10022022xex99.htm, filed 2022-11-01) ↗
Q2 2022Jul 3, 202211,500+15.0%Form 8-K (Earnings / Guidance Release) (pfe-07032022xex99.htm, filed 2022-07-28) ↗

Cite this data

StockData. (2026). Pfizer Full-Year Adjusted R&D Expense Guidance ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/guid-rd-low

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.